research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:10:34 ON 21 JUN 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:10:41 ON 21 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2005 HIGHEST RN 852602-49-4
DICTIONARY FILE UPDATES: 20 JUN 2005 HIGHEST RN 852602-49-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10789053.str



chain nodes :
7 8 9 10 28 29 30
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

chain bonds :
3-9 5-7 7-8 8-11 9-10 10-17 16-28 19-22 28-29 28-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 17-18
17-21 18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 5-6 5-7 7-8 9-10 17-18 17-21 18-19 19-20
20-21 28-29 28-30
exact bonds :
8-11 10-17 16-28 19-22
normalized bonds :
11-12 11-16 12-13 13-14 14-15 15-16 22-23 22-27 23-24 24-25 25-26 26-27

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS
29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:11:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:11:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 115 TO ITERATE

100.0% PROCESSED 115 ITERATIONS 84 ANSWERS
SEARCH TIME: 00.00.01

L3 84 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 10:11:14 ON 21 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jun 2005 VOL 142 ISS 26
FILE LAST UPDATED: 20 Jun 2005 (20050620/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 5 L3

=> s l3/p
L5 5 L3/P

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:740279 CAPLUS
DOCUMENT NUMBER: 141:260285
TITLE: Method for producing the enantiomeric forms of cis-1,3-cyclohexanediol derivatives using an enzymic resolution
INVENTOR(S): Holla, Wolfgang; Keil, Stefanie
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076390	A1	20040910	WO 2004-EP1580	20040219
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308350	A1	20040916	DE 2003-10308350	20030227
US 2004209931	A1	20041021	US 2004-789053	20040227
PRIORITY APPLN. INFO.:			DE 2003-10308350 A	20030227
			US 2003-487416P P	20030715

OTHER SOURCE(S): MARPAT 141:260285
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a method for producing chiral, non-racemic, disubstituted cis-1,3-cyclohexanediols I [R1 = R'; A = Ph, 5- to 10-membered heteroarom. (containing N, O, S), C8-14-aromatic, C3-8-cycloalkyl; R3 = H, F, Cl, Br, OH, NO2, CF3, OCF3, Cl-6-alkyl, C3-8-cycloalkyl, Ph; R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, OCHF2, OCF2CF3, OCF2CHF2, SCF3, OPh, C1-6-alkyl, O-(C1-6-alkyl), O-(C1-6-alkyl)-O-(C1-3-alkyl); n = 1 - 3; R2 = C1-8-alkyl, optionally, one or more CH2 may be replaced with an O, CO, S, SO, SO2 and substituted with 1 - 3 substituents (F, Cl, Br, CF3, Cn, NO2, NHAc, NHBoc, NHCOCMe3, OH, OCF3, O-(C1-6-alkyl), CO2H, CO2CH2Ph, CO2-(C1-6-alkyl), tetrazole, indole, (un)substituted thiazolidine-2,4-dione, C6-10-aryl), or, protecting group (PG) (e.g., CH2OCH2Ph, CH2Ph, CH2C6H4OMe-p, SiMe2CMe3)] using an enzymic resolution of racemates. The preparation of chiral cis-I is characterized by: (a) alkylation of (±)-cis-1,3-cyclohexanediol with R2X1 [X1 = Cl, Br, I, OSO2Me (OMs), OSO2C6H4Me-p (OTs), OSO2CF3 (OTf)] in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resolution of (±)-cis-I (R1 = H) with an acyl donor, R6Cl or (R6)2O [R6 = C(:O)-(C1-16-alkyl), C(:O)-(C2-16-alkenyl), C(:O)-(C3-16-alkynyl), C(:O)-(C3-16-cycloalkyl),

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-48-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755030-33-2 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 755030-34-3 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
optionally one or more CH2 may be replaced with O substituted with 1 - 3 substituents (F, Cl, Br, CF3, CN, NO2, OH, OMe, OEt, Ph, CO2-(C1-4-alkyl), CO2-(C2-4-alkenyl))], in an org. solvent contg. an enzyme; (c) chem. hydrolysis of chiral cis-I (R1 = R6); (d) alkylation of chiral cis-I (R1 = H) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent. Alternatively chiral cis-I is prepd. by: (a) alkylation of (±)-cis-1,3-cyclohexanediol with PG-X1 [X1 = Cl, Br, I, OMs, OTs, OTf] in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resoln. of (±)-cis-I (R1 = H, R2 = PG) with an acyl donor, R6Cl or (R6)2O, in an org. solvent contg. an enzyme; (c) chem. hydrolysis of chiral cis-I (R1 = R6, R2 = PG); (d) alkylation of chiral cis-I (R1 = H; R2 = PG) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent (e) deprotecting chiral cis-I (R2 = PG); (f) alkylation of chiral cis-I (R2 = H) with R2X1 in the presence of a base and a suitable solvent. Thus, cyclohexanediol deriv. II was prepd. from (±)-cis-1,3-cyclohexanediol via alkylation with Me 2-(bromomethyl)-6-methylbenzoate in NMP contg. KOCMe3, enzymic resoln. with vinyl acetate in CH2Cl2 contg. Novozym 435, alkylation of the resulting chiral (benzyloxy)cyclohexanol III with (iodomethyl)oxazole IV, and sapon. with NaOH in EtOH.

IT **501362-77-2P 710281-33-7P 710281-37-1P**
710281-48-4P 755030-33-2P 755030-34-3P
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn of the enantiomeric forms of cis-1,3-cyclohexanediol derivs. using an enzymic resolution)

RN 501362-77-2 CAPLUS
CN Benzoic acid, 2-{[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-33-7 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-37-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **755030-19-4P 755030-23-0P 755030-27-4P**
RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of; prepn of the enantiomeric forms of cis-1,3-cyclohexanediol derivs. using an enzymic resolution)

RN 755030-19-4 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755030-23-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755030-27-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:740108 CAPLUS
DOCUMENT NUMBER: 141:260734
TITLE: Preparation of diarylcycloalkyl oxazole derivatives and their use in the treatment of, e.g., fatty acid metabolism
INVENTOR(S): Goerlitzer, Jochen; Glombik, Heiner; Falk, Eugen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075815	A2	20040910	WO 2004-EP1584	20040219
WO 2004075815	A3	20041229		
W: AE, AE, AG, AL, AL, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308353	A1	20041202	DE 2003-10308353	20030227
US 2004204462	A1	20041014	US 2004-789019	20040227
PRIORITY APPLN. INFO.:			DE 2003-10308353 A	20030227
			US 2003-494911P P	20030813

OTHER SOURCE(S): MARPAT 141:260734
GI

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Title compds. I [A = cycloalkanediyl, cycloalkenediyl, etc.; B = Ph, heterocyclic, etc.; R1 = SCF3, OCF2-CHF2, phenoxy, etc.; R2 = H, CF3; R3 = H, alkyl; R4 = Ph, H, F, Cl, Br, etc.; R5 = H, F, Cl, Br, OH, etc.; X, Y = alkanediyl, etc.] are prepared For instance, 2-Methyl-6-[[((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid (II) is prepared in 7 steps using naphthalene-2-carboxaldehyde, diacetylmonooxime, 1,3-cyclohexanediol and 2-bromomethyl-6-methylbenzoic acid Me ester. II has an EC50 = 0.2 nM for the PPARα receptor. I are useful for treating disorders of the fatty acid metabolism and glucose utilization in addition to disorders of insulin resistance.

IT **755016-26-3P**, 2-[[((1R,3S)-3-((2-(3-Fluoro-5-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid methyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)

RN 755016-26-3 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-[3-fluoro-5-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT **755016-12-7P**, 2-Methyl-6-[[((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid **755016-13-8P**, 2-[[((1R,3S)-3-((2-(Benzo[1,3]dioxol-5-yl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid **755016-15-0P**, 2-[[((1R,3S)-3-(((2,3-Dihydrobenzo[1,4]dioxin-6-yl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid **755016-20-7P**, 2-[[((1R,3S)-3-[(5-Methyl-2-(4-((trifluoromethyl)sulfanyl)phenyl)oxazol-4-yl)methoxy]cyclohexyl)oxy)methyl]-6-methylbenzoic acid **755016-23-0P**, 2-[[((1R,3S)-3-[(5-Methyl-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]oxazol-4-yl)methoxy]cyclohexyl)oxy)methyl]-6-methylbenzoic acid **755016-24-1P**, 2-[[((1R,3S)-3-((5-Methyl-2-(4-phenoxyphenyl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid **755016-27-4P**, 2-[[((1R,3S)-3-((2-(3-(2-Methoxyethoxy)-5-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid **755016-28-5P**, 2-Methyl-6-[[((1R,3S)-3-((5-phenyl-2-(4-tolyl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid **755016-30-9P**, 2-[[((1R,3S)-3-((2-(3-Methoxyphenyl)-5-phenyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)

RN 755016-12-7 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-13-8 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-15-0 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 755016-20-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[4-[(trifluoromethyl)thio]phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-23-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-24-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-phenoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **755016-11-6P**, 2-Methyl-6-[[[(1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid methyl ester RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylcycloalkyl oxazole derivs. and their use in treatment
of, e.g., fatty acid metabolism)
RN 755016-11-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 755016-27-4 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-[3-(2-methoxyethoxy)-5-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-28-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-30-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:513338 CAPLUS
DOCUMENT NUMBER: 141:71532
TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators
INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schafer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 231,432.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
PRIORITY APPLN. INFO.:			DE 2001-10142734 A	20010831
			DE 2002-10223273 A	20020524
			US 2002-231432 A2	20020830

OTHER SOURCE(S): MARPAT 141:71532
GI



I



II

AB Title oxazoles I [Z = cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, etc.; R3 = H, Me; X, Y = alkyl (chains may contain 1 or more oxygens)] are prepared Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
O-alkylation with 4-(Iodomethyl)-2-(4-fluorophenyl)oxazole, sepn. of cis/trans isomers, HPLC resoln. of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was detd. [EC50 = 0.3 nM vs. PPARα],

IT **710281-44-0P**, 2-[[[(1R,3S)-3-[[2-(3-Bromophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-44-0 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **710281-30-4P**, Methyl 2-[[[(1R,3S)-3-[[2-(3-Fluorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoate
710281-32-6P, 2-[[[(1R,3S)-3-[[2-(3-Fluorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-33-7P, 2-[[[(1R,3S)-3-[[2-(3-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-34-8P, 2-[[[(1R,3S)-3-[[2-(3-Trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-35-9P, 2-[[[(1R,3S)-3-[[2-(3-Chlorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-36-0P, 2-[[[(1R,3S)-3-[[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-37-1P, 2-[[[(1R,3S)-3-[[2-(3-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-38-2P, 2-[[[(1R,3S)-3-[[2-(3,4-Dimethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-39-3P, 2-[[[(1R,3S)-3-[[2-(2,4-Dimethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-40-6P, 2-[[[(1R,3S)-3-[[2-(2-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-41-7P, 2-[[[(1R,3S)-3-[[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-42-8P, 2-[[[(1R,3S)-3-[[2-(3,4-Dimethoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-43-9P, 2-[[[(1R,3S)-3-[[2-(3-Cyanophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
710281-45-1P, 2-Methyl-6-[[[(1R,3S)-3-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-46-2P**, 2-Methyl-6-[[[(1S,3R)-3-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-48-4P**,

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
2-Methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-49-5P**, 2-Methyl-6-[[[(1S,3R)-3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]cyclohexyl]oxy]methyl]benzoic Acid **710281-50-8P**, 2-[[[(1R,3S)-3-[[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid **710281-51-9P**, 2-[[[(1S,3R)-3-[[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-30-4 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-32-6 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-33-7 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 710281-34-8 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-35-9 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-36-0 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 710281-37-1 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-38-2 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-39-3 CAPLUS

CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 710281-40-6 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-41-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-42-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-43-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-45-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-46-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-48-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-49-5 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-50-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-51-9 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501362-02-3P 501362-03-4P 501362-06-7P
501362-09-0P 501362-12-5P 501362-16-9P
501362-21-6P 501362-43-2P 501362-45-4P
501362-46-5P 501362-47-6P 501362-48-7P
501362-49-8P 501362-50-1P 501362-52-3P
501362-53-4P 501362-54-5P 501362-55-6P
501362-58-9P 501362-59-0P 501362-60-3P
501362-61-4P 501362-62-5P 501362-65-8P
501362-67-0P 501362-70-5P 501362-73-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and PPAR activating activity of; preparation of oxazole diaryl

cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-02-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-03-4 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-06-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-09-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-12-5 CAPLUS

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-16-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-21-6 CAPLUS
CN Benzoic acid, 2-[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-43-2 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501362-50-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-52-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-53-4 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-54-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 501362-45-4 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-46-5 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-47-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-48-7 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-49-8 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501362-55-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-58-9 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-59-0 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-60-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-62-5 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-65-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-67-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-08-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-11-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-14-7 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 501362-70-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-73-8 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501362-01-2P 501362-08-9P 501362-11-4P**
501362-14-7P 501362-20-5P 501362-42-1P
501362-69-2P 501362-72-7P 501362-75-0P
501362-77-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. and
the use thereof as PPAR activators)

RN 501362-01-2 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 501362-20-5 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-42-1 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 501362-69-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-72-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-75-0 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-77-2 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501362-44-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, cyanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-44-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



IT **501362-64-7P 501362-78-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-64-7 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 501362-78-3 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



ACCESSION NUMBER: 2003:202470 CAPLUS
DOCUMENT NUMBER: 138:238169
TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators
INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schaefer, Hans-Ludwing; Schwink, Lothar; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020269	A1	20030313	WO 2002-EP9221	20020817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
CA 2458210	AA	20030313	CA 2002-2458210	20020817
EE 200400059	A	20040415	EE 2004-59	20020817
EP 1425014	A1	20040609	EP 2002-797589	20020817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012158	A	20040713	BR 2002-12158	20020817
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
BG 108598	A	20050331	BG 2004-108598	20040224

PRIORITY APPLN. INFO.: DE 2001-10142734 A 20010831
DE 2002-10223273 A 20020524
WO 2002-EP9221 W 20020817

OTHER SOURCE(S): MARPAT 138:238169
GI



I



II

AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I [Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, C1-6-alkyl, O-(C1-6-alkyl); R3 = H, C1-6-alkyl; X, Y = C1-6-alkyl (chains may contain 1 or more oxygens)] to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(Iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined (EC50 = 0.3 nM vs. PPARα).

IT **501362-02-3P 501362-03-4P 501362-06-7P**
501362-09-0P 501362-12-5P 501362-16-9P
501362-21-6P 501362-43-2P 501362-45-4P
501362-46-5P 501362-47-6P 501362-48-7P
501362-49-8P 501362-50-1P 501362-52-3P
501362-53-4P 501362-54-5P 501362-55-6P
501362-58-9P 501362-59-0P 501362-60-3P
501362-61-4P 501362-62-5P 501362-65-8P
501362-67-0P 501362-70-5P 501362-73-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-02-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-03-4 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-06-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-09-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-12-5 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-46-5 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-47-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-48-7 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-49-8 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)





RN 501362-16-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-21-6 CAPLUS
CN Benzoic acid, 2-[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-43-2 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-45-4 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

RN 501362-50-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-52-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-53-4 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-54-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-55-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-58-9 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-59-0 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-60-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-62-5 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-65-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-67-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-70-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-73-8 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501362-01-2P 501362-08-9P 501362-11-4P**
501362-14-7P 501362-20-5P 501362-42-1P
501362-69-2P 501362-72-7P 501362-75-0P
501362-77-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. and
the use thereof as PPAR activators)

RN 501362-01-2 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 501362-08-9 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-11-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-14-7 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-20-5 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 501362-42-1 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 501362-69-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-72-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-75-0 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501362-78-3 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 501362-77-2 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501362-44-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, cyanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-44-3 CAPLUS
CN Benzoic acid, 2-[[[3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



IT **501362-64-7P 501362-78-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
RN 501362-64-7 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2000:772613 CAPLUS
DOCUMENT NUMBER:	133:335164
TITLE:	Tri-aryl acid derivatives as PPAR receptor ligands
INVENTOR(S):	Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael F.; Labaudiniere, Richard F.; Zhang, Litao; Caulfield, Thomas J.; Minnich, Anne; Bobko, Mark; Morris, Robert; Groneberg, Robert D.; Mcgarry, Daniel G.
PATENT ASSIGNEE(S):	Aventis Pharmaceuticals Products Inc., USA
SOURCE:	PCT Int. Appl., 257 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064876	A1	20001102	WO 2000-US11490	20000428
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371308	AA	20001102	CA 2000-2371308	20000428
EP 1177176	A1	20020206	EP 2000-930210	20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010126	A	20020226	BR 2000-10126	20000428
EE 200100558	A	20021216	EE 2001-558	20000428
NZ 515087	A	20031128	NZ 2000-515087	20000428
ZA 2001008800	A	20030210	ZA 2001-8800	20011024
NO 2001005226	A	20011205	NO 2001-5226	20011025
HR 2001000793	A1	20030228	HR 2001-793	20011026
PRIORITY APPLN. INFO.:			US 1999-131454P P	19990428
			WO 2000-US11490 W	20000428

OTHER SOURCE(S): MARPAT 133:335164
GI



I



II

AB This invention is directed to triaryl acid derivs. I and their salts, N-oxides, hydrates, solvates, and pharmaceutical compns. [wherein: Ar1, Ar2, Ar3 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl; A = bond, O, S, SO, SO2, CO, (un)substituted NH, NHCO, CONH, NHCONH, CH:N, etc.; B = bond, O, S, SO, SO2, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; D = bond, O, S, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; E = bond, CH2CH2; Z = (un)substituted CO2H, CHO, cyclo-imide, cyano, sulfonylaminocarbonyl, sulfonylamino, carbamoyl, tetrazolyl, etc.; R1, R3, R5, R7, R9, R11 = H, halo, alkyl, CO2H, alkoxycarbonyl, aralkyl; R2, R4, R6, R8, R10, R12 = (CH2)0-3X (where X = H or various substituents); n1 = 0-4; m1 = 0-4; n = 0-4; m = 0-5; p = 0-4; q = 0-6; with numerous provisos]. The compds. are PPAR receptor ligands, useful as agonists or antagonists thereof (no data). For instance, 2,6-dimethylbenzoic acid underwent a sequence of: (1) Me esterification, (2) benzylic monobromination, (3) etherification with 3-(quinolin-2-ylmethoxy)phenol, and (4) alkaline hydrolysis with NaOH in aqueous EtOH, to give title compound II.

IT **303218-47-5P 303219-55-8P 303219-57-0P**
303220-12-4P 303220-98-6P 303221-38-7P
303221-40-1P 303221-44-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tri-aryl acid derivs. as PPAR receptor ligands)

RN 303218-47-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-55-8 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303219-57-0 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(3-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 303221-44-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 303220-12-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303220-98-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-38-7 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(3-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-40-1 CAPLUS
CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)